Reading JYNT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track JYNT free→Reading JYNT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track JYNT free→NASDAQHealth CareMedical Care FacilitiesSnapshot 2026-06-12
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, but risk is elevated and the sector backdrop is a headwind. Earnings quality is neutral, and management's recent track record has been steady. Peer multiples imply a price about 197% below where it trades (it looks expensive on this basis); the read is rich, as it trades above peer multiples, and the longer horizon does not make that back through growth. Key factors to watch include guidance changes and sector trends, particularly how leading companies in the Healthcare sector perform. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 6 valuation methods, at three horizons. Current price $9.58. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $9.58, JYNT's earnings are too small for P/E to mean much; on sales it trades at 46× p/e (3.2× the 14× p/e peer median). At a normal multiple the price implies ~203% near-term growth vs our ~-29% forecast. That gap is an optionality premium a financial-multiple model can't price — our $3.16 fair value covers only the as-is business, low confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 203% near-term growth, well above our forecast of about -29%. This describes what's priced in, not a forecast of the move.
Flags: expensive valuation, weak execution quality, a turbulent sector regime (Heating).
For similar setups historically (n=889): about 49% saw a 20%+ drawdown, and roughly 85% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 3 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 1.25x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 50% for the rest of the cohort, n=2269).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates.
Not enough signal yet.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.04 → $0.07 (+68.8% / 30d). 0 raised, 1 cut, 4 covering analysts.
0 upgrades, 0 downgrades / 30d. 25% of analysts rate Buy.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$124.
How much price usually moves either way.
On a bad day, this stock has moved -$405.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $3,839.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-12
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
No named catalysts to watch right now. Check back after the next earnings report.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for JYNT yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
No material events in the last 90 days.
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Facilities.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
JYNT Joint Corp. (The) | Typical Show detailsSector percentile: 43 of 100 | expensive | elevated |
HCA HCA Healthcare | Above typical Show detailsSector percentile: 79 of 100 | fair | moderate |
THC Tenet Health | Above typical Show detailsSector percentile: 87 of 100 | fair | elevated |
EHC Encompass Health | Above typical Show detailsSector percentile: 95 of 100 | full | moderate |
UHS Universal Health Services | Above typical Show detailsSector percentile: 91 of 100 | inexpensive | elevated |
Not investment advice. As of 2026-06-12.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-12.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
No qualifying priorities for this snapshot. Check back after the next refresh.